Matches in SemOpenAlex for { <https://semopenalex.org/work/W1641154539> ?p ?o ?g. }
Showing items 1 to 69 of
69
with 100 items per page.
- W1641154539 endingPage "303" @default.
- W1641154539 startingPage "290" @default.
- W1641154539 abstract "Studies were conducted to assess the bioequivalence of a new antimycotic formulation, ciclopirox olamine lotion 1%, to an established compound, ciclopirox olamine cream 1%. Results of in vitro studies, using skin samples from human cadavers and domestic pigs, demonstrated that the two formulations equally penetrate all layers of the stratum corneum and inhibit the growth of Trichophyton mentagrophytes and Candida albicans. In vivo studies in guinea pigs and in human volunteers demonstrated the comparable therapeutic efficacy of the lotion and the cream in experimental trichophytosis. In addition, a multicenter, double-blind clinical trial was undertaken to compare ciclopirox olamine lotion 1% with the vehicle alone in the treatment of patients with tinea pedis. Patients with plantar, interdigital, or vesicular tinea pedis were enrolled in the studies. Patients were treated for 28 days. Clinical and mycological responses were determined during treatment and two weeks posttreatment. Ciclopirox olamine lotion 1% was found to be significantly more effective than its vehicle in the treatment of patients with common tinea pedis. Minor localized side effects (pruritus, burning sensation) were reported in 2% of 89 patients treated with ciclopirox olamine lotion 1%. The results demonstrate the bioequivalence of ciclopirox olamine lotion 1% and ciclopirox olamine cream 1% and confirm the clinical effectiveness and safety of the lotion in the treatment of tinea pedis, a generally recalcitrant fungal infection. It is concluded that ciclopirox olamine lotion 1% can be used as an alternative to ciclopirox olamine cream 1% for treatment of tinea pedis, tinea versicolor, tinea cruris, tinea corporis, and cutaneous candidiasis when the convenience and/or cosmetic elegance of a lotion is desired." @default.
- W1641154539 created "2016-06-24" @default.
- W1641154539 creator A5002785851 @default.
- W1641154539 creator A5007584430 @default.
- W1641154539 creator A5011931455 @default.
- W1641154539 creator A5017154400 @default.
- W1641154539 creator A5018445497 @default.
- W1641154539 creator A5026511947 @default.
- W1641154539 creator A5048901326 @default.
- W1641154539 creator A5071321508 @default.
- W1641154539 creator A5076121051 @default.
- W1641154539 creator A5078544653 @default.
- W1641154539 date "1989-05-01" @default.
- W1641154539 modified "2023-09-23" @default.
- W1641154539 title "Ciclopirox olamine lotion 1%: bioequivalence to ciclopirox olamine cream 1% and clinical efficacy in tinea pedis." @default.
- W1641154539 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/2663159" @default.
- W1641154539 hasPublicationYear "1989" @default.
- W1641154539 type Work @default.
- W1641154539 sameAs 1641154539 @default.
- W1641154539 citedByCount "5" @default.
- W1641154539 countsByYear W16411545392016 @default.
- W1641154539 crossrefType "journal-article" @default.
- W1641154539 hasAuthorship W1641154539A5002785851 @default.
- W1641154539 hasAuthorship W1641154539A5007584430 @default.
- W1641154539 hasAuthorship W1641154539A5011931455 @default.
- W1641154539 hasAuthorship W1641154539A5017154400 @default.
- W1641154539 hasAuthorship W1641154539A5018445497 @default.
- W1641154539 hasAuthorship W1641154539A5026511947 @default.
- W1641154539 hasAuthorship W1641154539A5048901326 @default.
- W1641154539 hasAuthorship W1641154539A5071321508 @default.
- W1641154539 hasAuthorship W1641154539A5076121051 @default.
- W1641154539 hasAuthorship W1641154539A5078544653 @default.
- W1641154539 hasConcept C112705442 @default.
- W1641154539 hasConcept C16005928 @default.
- W1641154539 hasConcept C2777220567 @default.
- W1641154539 hasConcept C2778217265 @default.
- W1641154539 hasConcept C2780986958 @default.
- W1641154539 hasConcept C42404028 @default.
- W1641154539 hasConcept C71924100 @default.
- W1641154539 hasConcept C98274493 @default.
- W1641154539 hasConceptScore W1641154539C112705442 @default.
- W1641154539 hasConceptScore W1641154539C16005928 @default.
- W1641154539 hasConceptScore W1641154539C2777220567 @default.
- W1641154539 hasConceptScore W1641154539C2778217265 @default.
- W1641154539 hasConceptScore W1641154539C2780986958 @default.
- W1641154539 hasConceptScore W1641154539C42404028 @default.
- W1641154539 hasConceptScore W1641154539C71924100 @default.
- W1641154539 hasConceptScore W1641154539C98274493 @default.
- W1641154539 hasIssue "3" @default.
- W1641154539 hasLocation W16411545391 @default.
- W1641154539 hasOpenAccess W1641154539 @default.
- W1641154539 hasPrimaryLocation W16411545391 @default.
- W1641154539 hasRelatedWork W1641154539 @default.
- W1641154539 hasRelatedWork W2103239020 @default.
- W1641154539 hasRelatedWork W2114259209 @default.
- W1641154539 hasRelatedWork W2133746904 @default.
- W1641154539 hasRelatedWork W2263981729 @default.
- W1641154539 hasRelatedWork W2301898032 @default.
- W1641154539 hasRelatedWork W2415153946 @default.
- W1641154539 hasRelatedWork W3157910350 @default.
- W1641154539 hasRelatedWork W4210519459 @default.
- W1641154539 hasRelatedWork W2944654754 @default.
- W1641154539 hasVolume "11" @default.
- W1641154539 isParatext "false" @default.
- W1641154539 isRetracted "false" @default.
- W1641154539 magId "1641154539" @default.
- W1641154539 workType "article" @default.